perspec tives adverse drug reactions or create more work, as we must now perform recurring, longitudinal assessment of this new type of data in the health system. We also do not know whether the incidence estimates of Schildcrout et al. are relevant to other health systems or even real for the Vanderbilt system. We do not know if the economic modeling is plausible or if there will be unintended consequences. However, we do know that the current acceptance of adverse drug reactions and inadequate efficacy should not be tolerated. We can do better, but it is still unclear whether we have the will to take preemptive action.
The PharmGKB (http://www.pharmgkb. org) is a publicly available Web-based knowledge base whose aim is to aid researchers in understanding how genetic variation among individuals contributes to differences in reactions to drugs. A visual summary of the data available and how these various types of information are integrated within the PharmGKB is provided in the PharmGKB Knowledge Pyramid (see Figure 1) .
The foundation of the knowledge base is the primary pharmacogenetics and pharmacogenomics literature that is annotated, aggregated, and integrated in the form of (i) gene variant annotations, (ii) drug-centered pathways, and (iii) very important pharmacogene (VIP) summaries. Gene-drug-disease relationships are extracted from the literature using manual curation and natural language-processing techniques. Variant annotations are the core component of the knowledge in PharmGKB. Each variant annotation is based on a published article and describes the reported association between a single variant (single-nucleotide polymorphism or haplotype) and a drug phenotype. Multiple variant annotations may be created for a single publication if it reports multiple associations between variants and drugs. Key study parameters such as study size, population ethnicity, and statistics (e.g., P value and odds ratio) are recorded within each annotation. 1 Diagrams and descriptions of drug-centered pathways depict the genes involved in the pharmacokinetics or pharmacodynamics of a particular drug and are based on published evidence. VIP gene summaries provide a concise overview of critical genes involved in drug response, with PharmGKB links to the literature, important variant details, noteworthy haplotypes, and relevant drugs.
Building on variant annotations, "clinical annotations" combine multiple-variant annotations into a single summary of the relevant variant-drug-phenotype association. For example, many studies have reported the relationship between the Level 3 annotations are based on a single significant (not yet replicated) study or annotation for a variant-drug combination evaluated in multiple studies but lacking clear evidence of an association. Level 4 annotations are based on a case report; on a study that did not achieve significance but is biologically plausible; or on in vitro, molecular, or functional assay evidence. In cases in which the only literature evidence available is that there is no association, no clinical annotation is written. The lack of evidence for an association can be important in a research setting, and so although variant annotations are created in these situations, they are not summarized as clinical annotations because they would have no clinical utility to a doctor, pharmacist, patient, or direct-to-consumer genotyping customer. Curators use their experience and judgment when assigning evidence levels. They may use their discretion to risk relative to other genotypes because the incidence of efficacy or adverse events for any given drug has usually not been quantified. Also, the distribution of genotypes for any given population is often not available. Although many groups use HapMap frequencies to calculate population major alleles or typical genotypes, the HapMap populations are small and ethnically very specific. Their frequencies do not necessarily represent larger population frequencies (nor were they meant to). Therefore, we do not report the risk of a particular drug response as compared with "normal" because normal is typically not well defined. We report the risk as compared with other possible genotypes.
Each clinical annotation is assigned a "level of evidence" score that is a measure of confidence in the association as determined by the PharmGKB curators. This score is based on several criteria, including replication of the association, P value (after correction for multiple-hypothesis testing, if applicable), and odds ratio, if available. Table 1 describes the four levels of evidence and the criteria for each, with an example from the knowledge base. Levels 1 and 2 are divided into A and B subtypes. Level 1 annotations involve a variant-drug combination in which the preponderance of evidence shows an association. The association must be replicated in more than one cohort with significant TPMT*3B variant (rs1800460) and adverse reactions to purine analogs. After gathering the relevant individual-variant annotations within the PharmGKB, we combine and summarize the associations from each publication to produce a single clinical annotation. Thus, each clinical annotation is linked to several PubMed identifiers that support the variant annotations and contain a summary for each genotype. In the case of TPMT*3B, the AA genotype contains two copies of the *3B variant and is associated with a significantly increased risk of side effects due to decreased enzyme levels; the AG genotype contains one copy of the *3B variant and is associated with a slightly increased risk of side effects due to moderately decreased enzyme levels; and the GG genotype contains no copies of the *3B variant and is not associated with increased risk of side effects (see Table 1 ).
The level of risk for any given genotype is reported in a relative fashion as compared with other genotypes. For example, the AA genotype is associated with an increased risk of side effects as compared with the AG and GG genotypes-but not necessarily at an increased risk of side effects for patients on the drug in general, as this would depend on a detailed examination of the target-population allele frequencies and the populations on which the original US Food and Drug Administration approval is based. Thus, we report Annotation based on a case report, nonsignificant study, or in vitro, molecular, or functional assay evidence only rs61750900 in UGT2B10 and nicotine: PharmGKB contains two in vitro studies for this association Drug: nicotine GG: The GG genotype is not associated with changes in nicotine metabolism/clearance in human liver microsomes from subjects with the GG genotype and HEK293 overexpressing UGT2B10 GT: The GT genotype is significantly associated with a decrease in nicotine metabolism/clearance in human liver microsomes from subjects with the GT genotype as compared with subjects with the GG genotype TT: The TT genotype is significantly associated with a decrease in nicotine metabolism/clearance in human liver microsomes from subjects with the TT genotype as compared with subjects with the GG genotype and HEK293 The PharmGKB is focused on pharmacogenomics knowledge and implementation. The clinical implementation of pharmacogenomics represents the top level of the PharmGKB knowledge pyramid (Figure 1) . PharmGKB supports several clinically relevant projects, including the data-sharing consortia and several implementation projects. For example, the Clinical Pharmacogenetics Implementation Consortium (CPIC) provides drug-dosing guidelines based on an individual's genotype if genetic information is already available. 4 CPIC guidelines help clinicians understand how available genetic test results can be used to optimize drug therapy, rather than whether tests should be ordered. Key assumptions underlying the CPIC guidelines are that clinical high-throughput and preemptive (pre-prescription) genotyping will become more widespread, and that clinicians will be faced with having patients' genotypes available even if they have not explicitly ordered a test with a specific drug in mind.
perspec tives
Pharmacogenetics and pharmacogenomics are at a critical juncture. As the field moves from the bench to clinical implementation, it requires a high-quality and reliable source of up-to-date information about human genetic variation and its
Individualized Dosing With Anesthetic Agents
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The development of fundamental pharmacokinetics and pharmacodynamics concepts has enabled anesthesiologists to choose and dose anesthetic agents on a rational basis. The application of these concepts to a variety of clinical scenarios and patient populations makes it possible to individualize the dose, thereby decreasing the risk of complications. as more knowledge is gained about the sometimes profound differences in drug response, empirical dosing such as in milligrams per kilogram of total body weight is disappearing from the anesthesia specialty.
Anesthesia is the application of two different classes of drugs to create unconsciousness and lack of response to painful surgical stimuli. 1 Hypnotic drugs (e.g., isoflurane, propofol) create progressively increasing degrees of central nervous system depression with increasing doses. In parallel to this therapeutic effect, cardiovascular and respiratory depression occurs as a side effect of the increasing hypnotic anesthetic drug dosing. Opioid drugs (e.g., fentanyl) create progressively increasing degrees of analgesic effect and respiratory depression with increasing doses. The hypnotic and analgesic doseconcentration-drug effects have been measured and understood using pharmacokinetics and pharmacodynamics concepts. 1 All of the above drug effects and side effects can be altered by different disease states (e.g., cardiovascular disease), altered physiological factors (e.g., blood loss), and patient covariates (e.g., age, weight, gender).
For any individual patient, the anesthesiologist who is present during the full
